146 related articles for article (PubMed ID: 6398313)
21. Experience with thymopentin in the treatment of periarthritis humeroscapularis, tendinitis, and gonarthrosis by local infiltration.
Pipino F; Vittore D
Arzneimittelforschung; 1988 Jan; 38(1):116-9. PubMed ID: 3284530
[TBL] [Abstract][Full Text] [Related]
22. Thymopentin (TP-5) potency in vivo is enhanced by slow infusion.
Audhya T; Goldstein G
Int J Pept Protein Res; 1983 Nov; 22(5):568-72. PubMed ID: 6360927
[TBL] [Abstract][Full Text] [Related]
23. Thymopentin in the treatment of alopecia areata.
Orecchia G
Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
[No Abstract] [Full Text] [Related]
24. Thymopentin in chronic Trichophyton rubrum infection.
Molin L; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():135-8. PubMed ID: 3898286
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica].
Greiner J; Miehe M; Weber H; Stoimenov A; Sönnichsen N; Diezel W
Dermatol Monatsschr; 1990; 176(2-3):157-62. PubMed ID: 2365110
[TBL] [Abstract][Full Text] [Related]
26. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
Djawari D; Bolla K; Haneke E
Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
[TBL] [Abstract][Full Text] [Related]
27. Thymopentin in the treatment of juvenile chronic arthritis.
Bardare M; Corona F; Ogliari MT; Cohen E
Clin Exp Rheumatol; 1990; 8(1):89-93. PubMed ID: 1971780
[TBL] [Abstract][Full Text] [Related]
28. [Prospects in the treatment of rheumatoid polyarthritis].
Crouzet J
Rev Rhum Mal Osteoartic; 1988 Apr; 55(6):472-4. PubMed ID: 3134690
[TBL] [Abstract][Full Text] [Related]
29. Modulation of immune response in aged humans through different administration modes of thymopentin.
Duchateau J; Servais G; Vreyens R; Delespesse G; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():94-101. PubMed ID: 3898299
[TBL] [Abstract][Full Text] [Related]
30. Influence of thymopentin on postsurgical immune deficiency: a clinical pilot study.
Faist E; Riedel A; Bolla K
Int J Clin Pharmacol Res; 1987; 7(1):83-7. PubMed ID: 3294617
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of various routes of administration of thymopentin (TP-5) with consideration of degradative mechanisms.
Audhya T; Goldstein G
Int J Pept Protein Res; 1983 Aug; 22(2):187-93. PubMed ID: 6352534
[TBL] [Abstract][Full Text] [Related]
32. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
34. Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.
Franchimont P; Bolla K
Surv Immunol Res; 1985; 4 Suppl 1():70-5. PubMed ID: 3898295
[TBL] [Abstract][Full Text] [Related]
35. Thymopentin (TP-5) in the treatment of rheumatoid arthritis.
Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP
Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797
[TBL] [Abstract][Full Text] [Related]
36. [Thymopentin and immune response in patients with cancer].
Petronella P; Ferrone R; Freda F; Valeriani G
Minerva Chir; 1989 Sep; 44(18):2017-20. PubMed ID: 2694011
[TBL] [Abstract][Full Text] [Related]
37. [Therapy of recurrent oral aphthae with thymopoetin pentapeptide].
Djawari D; Haneke E
Hautarzt; 1983 Sep; 34(9):463-4. PubMed ID: 6355012
[TBL] [Abstract][Full Text] [Related]
38. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
[TBL] [Abstract][Full Text] [Related]
39. [FDDF (fast dissolving dosage form) piroxicam for sublingual administration in the treatment of rheumatoid arthritis].
Montecucco C; Caporali R; Ronchetti A; Rossi S; Comaschi E
Minerva Med; 1994 Dec; 85(12):633-8. PubMed ID: 7854556
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial.
Furuzawa-Carballeda J; Cabral AR; Zapata-Zuñiga M; Alcocer-Varela J
J Rheumatol; 2003 Feb; 30(2):256-9. PubMed ID: 12563677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
